Michelle Xia

Michelle Xia
Born
Xia Yu

1966 or 1967 (age 58–59)[1]
Known forFounder, CEO, chairwoman and president of Akeso

Michelle Xia (Chinese: 夏瑜; born 1966 or 1967) is a Chinese biopharmaceutical executive. She founded Akeso in 2012 and serves as the company's chairwoman, president, and chief executive officer.[2][3]

Early life and education

Xia was born in Gansu province.[4] She is the daughter of two university-educated engineers.[1]

She earned a degree in biochemistry from Sun Yat-sen University in Guangzhou in 1988, and a doctorate in molecular biology and microbiology from Newcastle University in the UK.[1] She also undertook postgraduate study at the University of Glasgow.[5] In 1996, she moved to the United States to conduct cancer research at the University of Louisville.[1]

Career

Xia co‑founded Akeso in 2012 and has served as chairwoman, president and CEO since inception.[2] The company listed on the Main Board of the Hong Kong Stock Exchange in April 2020.[3] Earlier in her career she held scientific or leadership roles at Crown Bioscience, PDL BioPharma, and Bayer.[6] Since 2023, she has served on the board of Summit Therapeutics.[7]

Under Xia, Akeso have developed Ivonescimab, which appears to outperform Pembrolizumab (marketed as Keytruda), produced by Merck in the US.[4]

In March 2025, she was included in the "TIME100 Health" list.[8]

As of July 2025, Forbes estimates her net worth at US$1.2 billion.[1]

References

  1. ^ a b c d e Dolan, Kerry A. (16 July 2025). "How This New Biotech Billionaire Outmaneuvered Merck In China". Forbes. Retrieved 24 July 2025.
  2. ^ a b "Annual Report 2024" (PDF). Akeso, Inc. 30 March 2025. p. 37. Retrieved 14 November 2025.
  3. ^ a b "Global Offering (Prospectus)" (PDF). Hong Kong Exchanges and Clearing. 14 April 2020. Retrieved 14 November 2025.
  4. ^ a b Leong, Clarence (11 April 2025). "The Chinese CEO Who Believes Her Cancer Drug Can Beat Merck's Bestseller". The Wall Street Journal. Retrieved 24 July 2025.
  5. ^ Manalac, Tristan (17 September 2025). "Choosing China: Akeso's $3M Beginnings and the Rise of China's Biotech Sector". BioSpace. Retrieved 16 November 2025.
  6. ^ "Summit Therapeutics Reports Financial Results and Provides Corporate Update". US SEC (EDGAR). 10 May 2023. Retrieved 14 November 2025.
  7. ^ "Dr. Yu (Michelle) Xia". Summit Therapeutics. Retrieved 16 November 2025.
  8. ^ Hu, Charlotte (8 May 2025). "TIME100 Health: Michelle Xia". TIME. Retrieved 24 July 2025.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.